Very happy to share our paper in Nature Genetics reporting meningiomas are comprised of 3 DNA methylation groups with distinct outcomes, drivers, and therapeutic vulnerabilities. nature.com/articles/s4158…. RaleighLab Abrar Choudhury, MD, PhD Stephen Magill MD, PhD @chunkybungle UCSF Neurosurgery UCSF Helen Diller Family Comprehensive Cancer Ctr

Congratulations Shiao-Pei Weathers. Presenting her amazing correlative work with Atezo in newly dx GBM.

Outstanding collaboration between Dr Weathers, ⁦Jennifer Wargo MD⁩ and ⁦nadim_ajami⁩ on gut microbiome in newly diagnosed GBM. Exciting new data on potential role of the microbiome on response to therapy.

Third day of the National Cancer Advisory Board Meetings National Cancer Institute. The Cancer Moonshot 1.0 will be concluding next year and the new Cancer Moonshot 2.0 is focused on the following:

Happy to see young MDs participating in research reporting conferences 👨🏻‍⚕️🔁👨🏻‍🔬 #BTWarsaw22 #science

An honor to be invited and present at BrainTumorsWarsaw. Lots of fantastic science presented and discussed. Thank you prof. Bożena Kamińska-Kaczmarek and her incredible team for everything!

Thanks so much ⁦UCSF Neurosurgery⁩ for being one of sponsors for an inspiring day with ⁦National Brain Tumor Society⁩ for the Northern California Brain Tumor Walk! We will keep trying to find a cure!! ⁦John de Groot, MD⁩ ⁦Manish Aghi, MD PhD⁩ ⁦RaleighLab⁩ and so many others!!

GCAR Associate Clinical Scientist, Emma Viktoria Hyddmark at #AACR23 with the #GBMAGILE clinical trial in progress poster 🧠 #GBM #glioblastoma #clinicaltrial

Have you considered participating in a clinical trial? Get tips for navigating the process and overcoming barriers in accessing them during a free webinar. Register: bit.ly/MayWebinar23 #btsm #braintumor MD Anderson Cancer Center

Congratulations to our department chair Edward Chang, MD, on receiving Society of Neurological Surgeons's Winn Prize! 🎉 He is the 2nd UC San Francisco neurosurgeon to be honored with this prestigious award recognizing an outstanding commitment to neuroscience research. #SNS2023 #UCSFproud CNS

Go Global Coalition for Adaptive Research! So glad National Brain Tumor Society @NBTSCSO, John Higgins, Managing Director of the Brain Tumor Investment Fund, and NBTS' volunteers will be part of this way to raise awareness during #GrayMay

Thank you Nasdaq for inviting us to ring the closing bell in honor of National Brain Tumor Awareness Month! #GoGrayinMay

The Kintara team was honored to ring the @NASDAQ #ClosingBell today alongside Global Coalition for Adaptive Research and National Brain Tumor Society in commemoration of National #BrainTumor Awareness Month. #GoGrayinMay Learn more about our work: bit.ly/3Wmxc6G $KTRA #KTRA

Thank you to everyone who joined us Nasdaq today! National Brain Tumor Society National Foundation for Cancer Research AFCR StacheStrong Bayer | Pharmaceuticals Kazia Therapeutics Kintara Therapeutics, Inc. NASDAQ: KTRA Vigeo Therapeutics Biohaven Polaris Pharmaceuticals Brian Alexander, Sujuan Ba Patrick Wen, Ingo Mellighoff, Erik Sulman, John de Groot, MD, Andrew Lassman

Congratulations to Global Coalition for Adaptive Research & Kintara Therapeutics, Inc. NASDAQ: KTRA for ringing the NASDAQ closing bell with our #GBMAGILE partners, patients, caregivers, and physicians united to raise awareness of the critical, unmet need for new treatment options for patients with GBM.

GBM AGILE leadership gathering at #ASCO2023 Coming up on 4 years since the study opened to enrollment, we have exciting plans to maximize learning from every patient. Thank you trial leadership for your commitment to accelerating treatment discovery for patients with

William C Chen presenting his award-winning research on a biomarker that predicts #meningioma radiation response at #ASCO2023. Photo credit to John de Groot, MD Jennie Taylor and Susan Chang! UCSF Neurosurgery UCSF Helen Diller Family Comprehensive Cancer Ctr UC San Francisco

Exciting news from #ASCO23. The phase III INDIGO trial demonstrated very promising results. If approved, the drug vorasidenib could become a new standard of care for patients with grade 2 IDH mutant oligodendrogliomas and astrocytomas.

Really wonderful National Brain Tumor Society walk today. Nice to see so many clinicians, scientists, patients, and caregivers together! UCSF Neurosurgery UCSF Helen Diller Family Comprehensive Cancer Ctr UC San Francisco

Our newly activated trial is specifically designed for patients with oligodendroglioma (CIC mutated) and NF1-associated gliomas clinicaltrials.gov/ct2/show/NCT05…. Excited to announce this unique trial and accrue patients! #endcancer, MD Anderson Cancer Center